source
- Gossamer Bio regains rights to lung disease asset from Chiesi after Phase 3 failure, eyes FDA submissionGossamer Bio announced that it has taken back the rights to its inhaled pulmonary hypertension candidate from partner Chiesi after the drug failed to meet its primary endpoint in a Phase 3 trial.…
- AstraZeneca says Wainua failure won’t alter M&A plans, stays on track for $80B 2030 goalAstraZeneca said during its Q2 earnings presentation that the late‑stage failure of the antisense therapy Wainua in ATTR‑cardiomyopathy does not derail its goal of reaching $80 billion in revenue b…